A Phase 1 2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER U04): Substudy 04B